

## Thymoglobulin® [anti-thymocyte globulin (rabbit)] – Expanded indication

- On April 24, 2017, <u>Sanofi announced</u> the FDA approval of <u>Thymoglobulin [anti-thymocyte globulin (rabbit)]</u> injection, for the prophylaxis of acute rejection in patients receiving a kidney transplant. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.
  - Previously, Thymoglobulin was only approved for the treatment of acute rejection in patients receiving a kidney transplant in conjunction with concomitant immunosuppression.
- Kidney disease is the ninth leading cause of death in the U.S.; 468,000 patients are currently on dialysis for kidney failure, including an estimated 100,000 who are waiting for a kidney transplant.
- Kidney transplantation offers patients with end-stage renal disease a potential alternative to dialysis. With kidney transplantation, however, there is a risk of acute rejection, which can lead to graft complications and potential loss of the transplanted kidney.
- The approval of Thymoglobulin's expanded indication was based on two clinical studies of 508 patients at increased risk of acute rejection and/or delayed graft function randomized to Thymoglobulin or interleukin-2 receptor antagonists (IL2RA). The primary endpoint was treatment failure, defined as the occurrence of acute rejection, graft loss, death, or lost to follow-up within 12 months following transplantation.
  - The first study showed a significantly lower incidence of treatment failure in the Thymoglobulin group vs. the IL2RA group (25% vs. 38%; p = 0.02).
  - The second study demonstrated non-inferiority of Thymoglobulin to ILRA with treatment failure rates of 25% vs. 34%, with an estimated treatment group difference of -9% (95 % CI: -19.9% to 3.6%).
  - A pooled analysis of both studies showed a composite treatment failure rate of 25.1% with Thymoglobulin vs. 36% with the IL2RA group. The estimated between treatment group difference (Thymoglobulin to IL2RA) was -10.9% (95% CI: -18.8% to - 2.9%), which demonstrated superiority of Thymoglobulin for the prevention of acute rejection.
- Thymoglobulin carries a boxed warning for immunosuppression.
- The recommended dose of Thymoglobulin for the prophylaxis of acute rejection in patients receiving a kidney transplant is 1.5 mg/kg of body weight administered by intravenous (IV) infusion daily with the first dose initiated prior to reperfusion of the donor kidney. The usual duration of administration is 4 to 7 days.
  - The recommended dose of Thymoglobulin for treatment of acute rejection in patients receiving a kidney transplant is 1.5 mg/kg of body weight administered daily for 7 to 14 days.
  - Premedication with corticosteroids, acetaminophen, and/or an antihistamine 1 hour prior to each infusion of Thymoglobulin is recommended and may reduce the incidence and intensity of infusion-associated reactions.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.